TROG Cancer Research
Members Login   CQMS Login

Bladder, Kidney and Prostate trials now recruiting

TROG 16.03 (CORE) - this study aims to show that the addition of SBRT (stereotactic body radiotherapy) to standard of care improves progression free survival for patients with extra-cranial oligiometastatic disease that has spread from their lung, breast and/or prostate cancer

Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG

TROG 15.03 (FASTRACKII) - this study aims to evaluate the activity and efficacy of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of kidney cancers.

Primary sponsor: TROG
Collaborating group:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)


TROG 14.02 (RAIDER) - this international clinical trial plans to use daily imaging to determine the optimal radiation treatment for bladder cancer patients.

Primary sponsor: Institute of Cancer Research (ICR)
Collaborating groups: TROG

ANZUP 1303 (ENZARAD) - the study will compare the effectiveness of standard deprivation therapy and radiation therapy combined either with enzalutamide or currently available antiandrogen drugs for improving the survival in men with localised prostate cancer at high risk of recurrence.

Primary sponsor: ANZUP
Collaborating group: TROG (TROG 14.01)

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.